AbbVie's Rinvoq approved for giant cell arteritis in US; Relmada reports Phase 2 bladder cancer data; Novo Nordisk Foundation ...

Eli Lilly partners with Creyon Bio in $13M upfront deal, potential $1B+ milestone payments. CEO Serge Messerlian leads ...

Venture-backed Devoted Health seems to be weathering the Medicare Advantage storm, according to an Endpoints News analysis of ...

Pfizer is expanding its multibillion-dollar cost-cutting effort that began in 2023, announcing $1.7 billion in new planned ...

AstraZeneca and Novartis emphasize US manufacturing capacity to avoid potential pharma tariffs, with Novartis aiming for 100% ...

In an unlikely partnership between two rivals, Hims & Hers said its members will now be able to get Novo Nordisk’s weight ...

Novartis reports strong Q1 2025 with $13.2B in sales, beating forecasts. Key drugs Xolair, Zolgensma, Kisqali exceed ...

The fate of a small, privately-held biotech’s new drug has been delayed, in what appears to be a sign that broad cuts to the ...

Octagon Therapeutics, led by CEO Isaac Stoner, is shutting down after halting work on B cell immunomodulator and facing ...

WuXi AppTec’s revenue rose for the first few months of 2025, signaling that pressures from the proposed Biosecure Act may be ...

Vertex Pharmaceuticals, Amgen and Jazz Pharmaceuticals are among companies that received a positive opinion from European ...

As it awaits an FDA approval decision on apitegromab for spinal muscular atrophy, Scholar Rock is reshaping its leadership ...